Printer Friendly
The Free Library
19,573,952 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

A.P. Pharma to Hold Third Quarter Conference Call November 7, 2002.


Business Editors & Health/Medical Writers

REDWOOD CITY Redwood City, city (1990 pop. 66,072), seat of San Mateo co., W Calif., on San Francisco Bay; inc. 1868. Manufactures include commmunications, electrical, electronic, and medical equipment. , Calif.--(BUSINESS WIRE)--Oct. 31, 2002

A.P. Pharma, Inc. (Nasdaq:APPA), a specialty pharmaceutical company, will release its 2002 third quarter results prior to market open on Thursday, November 7, 2002.

Paul Goddard This article is about an English footballer. For the Australian actor of the same name, see Paul Goddard (actor).
Paul Goddard (b. 12 October, 1959 in Harlington, Middlesex) is a former professional footballer and football manager.
, chairman, Michael O'Connell, president and chief executive officer, and Gordon Sangster, chief financial officer, will be hosting an investment-community conference call beginning at 11:00 a.m. Eastern Time (8:00 a.m. Pacific Time) on Thursday, November 7, 2002 to discuss the results and to answer questions.

To participate in the live call by telephone, please dial (888) 803-8290 from the U.S., and for international callers, please dial (706) 634-1287. A telephone replay will be available for 48 hours by dialing (800) 642-1687 from the U.S., or (706) 645-9291 for international callers, and entering reservation number 6433506.

Individuals interested in listening to the conference call via the Internet may do so by visiting www.appharma.com. A replay will be available on the Company's Web site for 14 days.

About A.P. Pharma

A.P. Pharma is a specialty pharmaceutical company focused on the development of ethical (prescription) pharmaceuticals utilizing its proprietary polymer-based drug delivery systems. The Company's primary focus is the development and commercialization of its bioerodible injectable in·ject·a·ble
adj.
Capable of being injected. Used of a drug.

n.
A drug or medicine that can be injected.
 and implantable systems under the trade name Biochronomer. Initial targeted areas of application for the Company's drug delivery technology include pain management, inflammation, oncology oncology /on·col·o·gy/ (ong-kol´ah-je) the sum of knowledge regarding tumors; the study of tumors.

on·col·o·gy
n.
 and ophthalmology ophthalmology (ŏf'thălmŏl`əjē), branch of medicine specializing in the anatomy, function and diseases of the eye. Ophthalmologists specialize in the medical and surgical treatment of eye disorders, vision measurements for  applications. The Company's product development programs are funded by royalties from topical products currently marketed by pharmaceutical partners and by proceeds from the divestiture The breakup of AT&T. By federal court order, AT&T divested itself on January 1, 1984 of its 23 operating companies, which became known as the Regional Bell Operating Companies (RBOCs).  of its cosmeceutical cos·me·ceu·ti·cal
n.
A cosmetic that has or is purported to have medicinal properties.
 product lines as well as fees it receives from collaborative partners. For further information visit the Company's Web site at www.appharma.com.
COPYRIGHT 2002 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2002, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Oct 31, 2002
Words:289
Previous Article:Comfort & Joy: Neiman Marcus Celebrates 95 Years With a Gala in It's Flagship Store.
Next Article:Fitch Affirms Ford, Ford Credit, Hertz & Related Entities Ratings.



Related Articles
A.P. Pharma Reports First Quarter Results; Clinical Program for APF112 Initiated in 2002; Royalty Income Up 39% Over First Quarter 2001.
A.P. Pharma Reports Second Quarter Financial Results; Royalty Income Continues to Increase; Clinical Programs Advance with Additional Corporate...
A.P. Pharma Reports Third Quarter Financial Results; Third Quarter Royalty Income Increases 30%.
A.P. Pharma Reports First Quarter Results; Royalty Income Increases by 14% Over Q1 2002.
A.P. Pharma Reports Second Quarter Results; APF112 Phase II Clinical Package Submitted for FDA Review; Royalty Income Increases 11% Over 2Q 2002.
A.P. Pharma to Hold Third Quarter Conference Call November 7, 2003.
A.P. Pharma Reports Third Quarter Results; APF112 Phase II Clinical Trial Initiated; Royalty Income Increases 23% Over Q3 2002.
A.P. Pharma to Hold 2004 Third Quarter Financial Results Conference Call November 15.
A.P. Pharma to Hold 2005 Third Quarter Financial Results Conference Call November 2.
A.P. Pharma to Hold 2006 Third Quarter Financial Results Conference Call November 7.

Terms of use | Copyright © 2012 Farlex, Inc. | Feedback | For webmasters | Submit articles